Company news

Biofrontera Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update

May 14, 2024

Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024

May 5, 2024

Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants

May 2, 2024

Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals

March 25, 2024

Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update

March 14, 2024

Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024

March 7, 2024

Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules

February 22, 2024

Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG

February 19, 2024

Biofrontera Inc. Announces Private Placement of Up To $16.0 Million Priced at Market per Nasdaq Rules

February 19, 2024

Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use

February 4, 2024

Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023

January 10, 2024

Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update

November 8, 2023

Biofrontera Inc. to Report Third Quarter 2023 Financial Results on November 9 and Hold Conference Call on November 10

November 2, 2023

Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules

October 30, 2023

Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)

October 9, 2023

Biofrontera Inc. Announces Preliminary Third Quarter Revenues

October 3, 2023

Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts

August 28, 2023

Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)

August 27, 2023

Biofrontera Inc. Reports Second Quarter 2023 Financial Results and Provides a Business Update

August 10, 2023

Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Basal Cell Carcinoma

August 9, 2023

Biofrontera Inc. Announces Preliminary Second Quarter Revenues are Up 26% to 31%

July 12, 2023

Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors

July 11, 2023

Biofrontera Inc. Announces 1-for-20 Reverse Stock Split

July 2, 2023

Biofrontera Inc. Sponsors The Sun Bus, Delivering Free Mobile Skin Cancer Screenings Across the U.S.

June 11, 2023

Biofrontera Inc. Begins Development of a Portable Photodynamic Therapy Lamp for Use with Ameluz(R)-PDT

May 31, 2023

Biofrontera Inc. Names Founder and Executive Chairman Hermann Luebbert as Chief Executive Officer

May 29, 2023

Biofrontera Inc. Announces U.S. Patent Issued for Photodynamic Therapy Protocol with Reduced Side Effects

May 14, 2023

Biofrontera Inc. Reports First Quarter 2023 Financial Results and Provides a Business Update

May 11, 2023

Biofrontera Inc. Announces Resignation of CEO

May 11, 2023

Biofrontera Inc. Announces New Secured Line of Credit up to $6.5 Million

May 10, 2023

Biofrontera Collaborates with The Skin Cancer Foundation to Raise Awareness of Skin Cancer Prevention

May 8, 2023

Biofrontera Inc. to Report First Quarter 2023 Financial Results on May 12, 2023

April 27, 2023

Biofrontera Inc. Announces Last Patient Out in Phase I Study to Evaluate Safety and Tolerability in Treating Actinic Keratosis Using 3 Tubes of Ameluz(R)

April 25, 2023

Biofrontera Inc. Makes Transformative Investment in Its' Dermatology Salesforce

March 26, 2023

CORRECTING AND REPLACING: Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results

March 8, 2023

Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results

March 7, 2023

Biofrontera, Inc. to Present at the 35th Annual ROTH Conference on March 13, 2023

March 1, 2023

Biofrontera Inc. to Report Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023

February 21, 2023

Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2022

January 8, 2023

Biofrontera Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk

January 8, 2023

Biofrontera Inc. Announces Voting Results from 2022 Annual Meeting of Stockholders

December 15, 2022

Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz®-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk

November 20, 2022

Biofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update

November 13, 2022

Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022

November 9, 2022

Biofrontera Inc. Fully Exercises Recently Acquired Options to Purchase Shares of Biofrontera AG

November 7, 2022

Biofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG

October 30, 2022

Biofrontera Inc. Names Fred Leffler as Chief Financial Officer

October 23, 2022

Biofrontera Inc. to Sponsor the 2022 Fall Clinical Dermatology Conference

October 17, 2022

Biofrontera Inc. Adopts Limited Duration Shareholder Rights Plan

October 13, 2022

Biofrontera Inc. Announces Preliminary Product Revenues for the Third Quarter of 2022

October 4, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 20 calls. Every call is listed under its year.